Sonnet BioTherapeutics SONN Stock
Sonnet BioTherapeutics Price Chart
Sonnet BioTherapeutics SONN Financial and Trading Overview
| Sonnet BioTherapeutics stock price | 2 USD |
| Previous Close | 1.75 USD |
| Open | 1.77 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 1.73 - 1.8 USD |
| 52 Week Range | 1.08 - 26.4 USD |
| Volume | 9.53K USD |
| Avg. Volume | 103.6K USD |
| Market Cap | 5.43M USD |
| Beta (5Y Monthly) | 1.116 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23 USD |
SONN Valuation Measures
| Enterprise Value | 2.6M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.62989324 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 42.059284 |
| Price/Book (mrq) | 2.112172 |
| Enterprise Value/Revenue | 20.115 |
| Enterprise Value/EBITDA | -0.18 |
Trading Information
Sonnet BioTherapeutics Stock Price History
| Beta (5Y Monthly) | 1.116 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 26.4 USD |
| 52 Week Low | 1.08 USD |
| 50-Day Moving Average | 1.89 USD |
| 200-Day Moving Average | 2.94 USD |
SONN Share Statistics
| Avg. Volume (3 month) | 103.6K USD |
| Avg. Daily Volume (10-Days) | 18.21K USD |
| Shares Outstanding | 3.07M |
| Float | 2.71M |
| Short Ratio | 7.85 |
| % Held by Insiders | 9.22% |
| % Held by Institutions | 3.52% |
| Shares Short | 424.16K |
| Short % of Float | 14.22% |
| Short % of Shares Outstanding | 13.81% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:26 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | September 30, 2023 |
| Most Recent Quarter (mrq) | December 31, 2023 |
| Next Fiscal Year End | September 30, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -6866.052% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -175.80% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 129.18K USD |
| Revenue Per Share (ttm) | 0.07 USD |
| Quarterly Revenue Growth (yoy) | -50.00000000000000000000000000000000% |
| Gross Profit (ttm) | N/A |
| EBITDA | -14446249 USD |
| Net Income Avi to Common (ttm) | -14459061 USD |
| Diluted EPS (ttm) | -0.83 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.02M USD |
| Total Cash Per Share (mrq) | 0.98 USD |
| Total Debt (mrq) | 186.69K USD |
| Total Debt/Equity (mrq) | 7.26 USD |
| Current Ratio (mrq) | 1.742 |
| Book Value Per Share (mrq) | 0.838 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18518408 USD |
| Levered Free Cash Flow (ttm) | -13563445 USD |
Profile of Sonnet BioTherapeutics
| Country | United States |
| State | NJ |
| City | Princeton |
| Address | 100 Overlook Center |
| ZIP | 08540 |
| Phone | 609 375 2227 |
| Website | https://www.sonnetbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Q&A For Sonnet BioTherapeutics Stock
What is a current SONN stock price?
Sonnet BioTherapeutics SONN stock price today per share is 2 USD.
How to purchase Sonnet BioTherapeutics stock?
You can buy SONN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sonnet BioTherapeutics?
The stock symbol or ticker of Sonnet BioTherapeutics is SONN.
Which industry does the Sonnet BioTherapeutics company belong to?
The Sonnet BioTherapeutics industry is Biotechnology.
How many shares does Sonnet BioTherapeutics have in circulation?
The max supply of Sonnet BioTherapeutics shares is 3.07M.
What is Sonnet BioTherapeutics Price to Earnings Ratio (PE Ratio)?
Sonnet BioTherapeutics PE Ratio is now.
What was Sonnet BioTherapeutics earnings per share over the trailing 12 months (TTM)?
Sonnet BioTherapeutics EPS is -0.83 USD over the trailing 12 months.
Which sector does the Sonnet BioTherapeutics company belong to?
The Sonnet BioTherapeutics sector is Healthcare.
Sonnet BioTherapeutics SONN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}